0 13 IL-2-mediated il-2-mediated JJ 14 18 cell cell NN 19 24 cycle cycle NN 25 36 progression progression NN 37 40 and and CC 41 51 inhibition inhibition NN 52 54 of of IN 55 64 apoptosis apoptosis NN 65 69 does do VBZ 70 73 not not RB 74 81 require require VB 82 90 NF-kappa NF-kappa NNP 91 92 B B NNP 93 95 or or CC 96 106 activating activate VBG 107 116 protein-1 protein-1 NN 117 127 activation activation NN 128 130 in in IN 131 138 primary primary JJ 139 144 human human JJ 145 146 T t NN 147 152 cells cell NNS 152 153 . . . 155 158 The the DT 159 163 IL-2 il-2 NN 164 170 growth growth NN 171 178 hormone hormone NN 179 181 is be VBZ 182 185 the the DT 186 191 major major JJ 192 198 growth growth NN 199 205 factor factor NN 206 208 of of IN 209 218 activated activate VBN 219 220 T t NN 221 232 lymphocytes lymphocyte NNS 233 239 during during IN 240 241 a a DT 242 252 developing develop VBG 253 259 immune immune JJ 260 268 response response NN 268 269 . . . 270 274 IL-2 il-2 NN 275 277 is be VBZ 278 286 required require VBN 287 290 not not RB 291 295 only only RB 296 299 for for IN 300 304 cell cell NN 305 310 cycle cycle NN 311 322 progression progression NN 323 326 but but CC 327 331 also also RB 332 334 to to TO 335 342 protect protect VB 343 355 Ag-activated ag-activated JJ 356 357 T t NN 358 363 cells cell NNS 364 368 from from IN 369 379 programmed program VBN 380 384 cell cell NN 385 390 death death NN 390 391 . . . 392 394 In in IN 395 402 several several JJ 403 407 cell cell NN 408 413 types type NNS 413 414 , , , 415 425 activation activation NN 426 428 of of IN 429 437 NF-kappa NF-kappa NNP 438 439 B B NNP 440 446 and/or and/or CC 447 457 activating activate VBG 458 467 protein-1 protein-1 NN 468 469 ( ( ( 469 473 AP-1 ap-1 NN 473 474 ) ) ) 475 478 has have VBZ 479 483 been be VBN 484 496 demonstrated demonstrate VBN 497 499 to to TO 500 502 be be VB 503 512 extremely extremely RB 513 522 important important JJ 523 525 in in IN 526 534 blocking block VBG 535 544 apoptosis apoptosis NN 544 545 . . . 546 548 To to TO 549 558 determine determine VB 559 566 whether whether IN 567 573 either either DT 574 576 or or CC 577 581 both both DT 582 584 of of IN 585 590 these these DT 591 604 transcription transcription NN 605 612 factors factor NNS 613 616 are be VBP 617 625 involved involve VBN 626 628 in in IN 629 633 cell cell NN 634 642 survival survival NN 643 645 or or CC 646 650 cell cell NN 651 656 cycle cycle NN 657 668 progression progression NN 669 671 in in IN 672 680 response response NN 681 683 to to TO 684 688 IL-2 il-2 NN 688 689 , , , 690 697 primary primary JJ 698 703 human human JJ 704 705 T t NN 706 711 cells cell NNS 712 722 responsive responsive JJ 723 725 to to TO 726 729 the the DT 730 736 growth growth NN 737 743 factor factor NN 744 748 were be VBD 749 757 analyzed analyze VBN 758 761 for for IN 762 770 NF-kappa NF-kappa NNP 771 772 B B NNP 773 776 and and CC 777 781 AP-1 ap-1 NN 782 792 activation activation NN 792 793 . . . 794 797 The the DT 798 805 current current JJ 806 811 study study NN 812 819 clearly clearly RB 820 832 demonstrates demonstrate VBZ 833 837 that that IN 838 842 IL-2 il-2 NN 843 847 does do VBZ 848 851 not not RB 852 858 induce induce VB 859 860 I i NN 861 866 kappa kappa NN 867 868 B B NNP 869 874 alpha alpha NN 875 886 degradation degradation NN 887 889 or or CC 890 898 NF-kappa NF-kappa NNP 899 900 B B NNP 901 911 activation activation NN 912 914 in in IN 915 922 primary primary JJ 923 928 human human JJ 929 930 T t NN 931 936 cells cell NNS 937 941 that that WDT 942 949 respond respond VBP 950 952 to to TO 953 957 IL-2 il-2 NN 958 960 by by IN 961 969 entering enter VBG 970 973 the the DT 974 978 cell cell NN 979 984 cycle cycle NN 985 988 and and CC 989 997 avoiding avoid VBG 998 1007 apoptosis apoptosis NN 1007 1008 . . . 1009 1018 Similarly similarly RB 1018 1019 , , , 1020 1024 IL-2 il-2 NN 1025 1032 neither neither CC 1033 1042 activates activate VBZ 1043 1046 JNK JNK NNP 1047 1050 nor nor CC 1051 1060 increases increase VBZ 1061 1065 AP-1 ap-1 NN 1066 1073 binding binding NN 1074 1082 activity activity NN 1083 1085 to to TO 1086 1087 a a DT 1088 1097 consensus consensus NN 1098 1120 o-tetradecanoylphorbol o-tetradecanoylphorbol NN 1121 1131 13-acetate 13-acetate NN 1132 1133 ( ( ( 1133 1136 TPA TPA NNP 1136 1137 ) ) ) 1138 1146 response response NN 1147 1154 element element NN 1154 1155 . . . 1156 1158 On on IN 1159 1162 the the DT 1163 1168 other other JJ 1169 1173 hand hand NN 1173 1174 , , , 1175 1178 the the DT 1179 1185 growth growth NN 1186 1192 factor factor NN 1193 1197 does do VBZ 1198 1204 induce induce VB 1205 1208 the the DT 1209 1219 activation activation NN 1220 1222 of of IN 1223 1228 STAT3 STAT3 NNP 1229 1232 and and CC 1233 1238 STAT5 STAT5 NNP 1239 1241 in in IN 1242 1247 these these DT 1248 1253 cells cell NNS 1253 1254 , , , 1255 1257 as as IN 1258 1261 has have VBZ 1262 1266 been be VBN 1267 1277 previously previously RB 1278 1290 demonstrated demonstrate VBN 1290 1291 . . . 1292 1297 These these DT 1298 1302 data datum NNS 1303 1307 show show VBP 1308 1312 that that IN 1313 1320 neither neither CC 1321 1329 NF-kappa NF-kappa NNP 1330 1331 B B NNP 1332 1335 nor nor CC 1336 1340 AP-1 ap-1 NN 1341 1351 activation activation NN 1352 1354 is be VBZ 1355 1363 required require VBN 1364 1367 for for IN 1368 1381 IL-2-mediated il-2-mediated JJ 1382 1390 survival survival NN 1391 1393 or or CC 1394 1398 cell cell NN 1399 1404 cycle cycle NN 1405 1416 progression progression NN 1417 1419 in in IN 1420 1429 activated activate VBN 1430 1437 primary primary JJ 1438 1443 human human JJ 1444 1445 T t NN 1446 1451 cells cell NNS 1451 1452 . . .